These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 35053170)

  • 1. MDM2-Driven Ubiquitination Rapidly Removes p53 from Its Cognate Promoters.
    Henningsen KM; Manzini V; Magerhans A; Gerber S; Dobbelstein M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin.
    Hu B; Gilkes DM; Farooqi B; Sebti SM; Chen J
    J Biol Chem; 2006 Nov; 281(44):33030-5. PubMed ID: 16905541
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the interaction mechanisms of a p53 peptide and nutlin with the MDM2 and MDMX proteins: a Brownian dynamics study.
    ElSawy KM; Verma CS; Joseph TL; Lane DP; Twarock R; Caves LS
    Cell Cycle; 2013 Feb; 12(3):394-404. PubMed ID: 23324352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of p53 DNA binding function by the MDM2 protein acidic domain.
    Cross B; Chen L; Cheng Q; Li B; Yuan ZM; Chen J
    J Biol Chem; 2011 May; 286(18):16018-29. PubMed ID: 21454483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional analysis and consequences of Mdm2 E3 ligase inhibition in human tumor cells.
    Wade M; Li YC; Matani AS; Braun SM; Milanesi F; Rodewald LW; Wahl GM
    Oncogene; 2012 Nov; 31(45):4789-97. PubMed ID: 22266850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
    Okamoto K; Taya Y; Nakagama H
    FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation.
    Mungamuri SK; Qiao RF; Yao S; Manfredi JJ; Gu W; Aaronson SA
    Cell Rep; 2016 Mar; 14(11):2528-37. PubMed ID: 26971997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells.
    Egorova O; Lau HH; McGraphery K; Sheng Y
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells.
    Vaseva AV; Marchenko ND; Moll UM
    Cell Cycle; 2009 Jun; 8(11):1711-9. PubMed ID: 19411846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The degradation of p53 and its major E3 ligase Mdm2 is differentially dependent on the proteasomal ubiquitin receptor S5a.
    Sparks A; Dayal S; Das J; Robertson P; Menendez S; Saville MK
    Oncogene; 2014 Sep; 33(38):4685-96. PubMed ID: 24121268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
    Ghosh M; Huang K; Berberich SJ
    Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Controlled access of p53 to the nucleus regulates its proteasomal degradation by MDM2.
    Davis JR; Mossalam M; Lim CS
    Mol Pharm; 2013 Apr; 10(4):1340-9. PubMed ID: 23398638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mdm2 RING mutation enhances p53 transcriptional activity and p53-p300 interaction.
    Clegg HV; Itahana Y; Itahana K; Ramalingam S; Zhang Y
    PLoS One; 2012; 7(5):e38212. PubMed ID: 22666487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
    Aziz MH; Shen H; Maki CG
    Oncogene; 2011 Nov; 30(46):4678-86. PubMed ID: 21643018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.
    Saha MN; Jiang H; Jayakar J; Reece D; Branch DR; Chang H
    Cancer Biol Ther; 2010 Jun; 9(11):936-44. PubMed ID: 20418664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 regulation: teamwork between RING domains of Mdm2 and MdmX.
    Wang X
    Cell Cycle; 2011 Dec; 10(24):4225-9. PubMed ID: 22134240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oligomerization conditions Mdm2-mediated efficient p53 polyubiquitylation but not its proteasomal degradation.
    Hjerpe R; Aillet F; Lopitz-Otsoa F; Lang V; Torres-Ramos M; Farrás R; Hay RT; Rodríguez MS
    Int J Biochem Cell Biol; 2010 May; 42(5):725-35. PubMed ID: 20080206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.